These developments gave hope for new tools in the clinical management of patients with GRPR-expressing tumors, such as prostate and breast cancer, which have high incidence of GRPR-overexpression (Baun et al. 2024; D’Onofrio et al. 2023; Dalm et al. 2024). Here, GRPR is linked to breast carcinoma.